Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

RVNC | Revance Therapeutics, Inc.

IndexRUT P/E- EPS (ttm)-4.53 Insider Own1.10% Shs Outstand83.69M Perf Week-22.56%
Market Cap1.17B Forward P/E- EPS next Y-0.97 Insider Trans-21.48% Shs Float81.31M Perf Month-30.09%
Income-357.80M PEG- EPS next Q-0.75 Inst Own89.40% Short Float / Ratio17.60% / 8.29 Perf Quarter-51.35%
Sales186.40M P/S6.30 EPS this Y-17.60% Inst Trans16.26% Short Interest14.31M Perf Half Y-58.63%
Book/sh0.32 P/B40.66 EPS next Y66.80% ROA-58.70% Target Price39.27 Perf Year-49.57%
Cash/sh3.54 P/C3.68 EPS next 5Y11.60% ROE-903.30% 52W Range11.10 - 37.98 Perf YTD-29.52%
Dividend- P/FCF- EPS past 5Y-4.10% ROI-87.30% 52W High-65.75% Beta0.87
Dividend %- Quick Ratio4.70 Sales past 5Y247.40% Gross Margin61.50% 52W Low17.21% ATR1.20
Employees534 Current Ratio5.10 Sales Q/Q104.60% Oper. Margin- RSI (14)27.20 Volatility10.27% 6.14%
OptionableYes Debt/Eq14.77 EPS Q/Q8.30% Profit Margin- Rel Volume2.22 Prev Close12.47
ShortableYes LT Debt/Eq14.19 EarningsAug 08 AMC Payout- Avg Volume1.73M Price13.01
Recom1.90 SMA20-21.74% SMA50-32.75% SMA200-51.72% Volume3,823,236 Change4.33%
Date Action Analyst Rating Change Price Target Change
Aug-16-23Upgrade Exane BNP Paribas Underperform → Neutral $20
Oct-11-22Initiated Morgan Stanley Equal-Weight $27
Sep-22-22Initiated Goldman Buy $33
Oct-25-21Downgrade Wells Fargo Overweight → Equal Weight $35 → $17
Oct-15-20Reiterated Needham Buy $36 → $42
Aug-11-20Resumed Mizuho Buy $32
Mar-23-20Downgrade Goldman Buy → Neutral $32 → $15
Dec-02-19Initiated Goldman Buy
Oct-30-19Upgrade Wells Fargo Market Perform → Outperform $20
Jun-11-19Initiated Barclays Overweight $28
Sep-19-23 04:18PM
Sep-06-23 02:27PM
Aug-29-23 12:43AM
10:43AM Loading…
Aug-22-23 10:43AM
Aug-21-23 04:09AM
Aug-14-23 04:03PM
Aug-08-23 06:15PM
Aug-03-23 09:19AM
Aug-01-23 08:00AM
Jul-29-23 11:39AM
03:00PM Loading…
Jul-13-23 03:00PM
Jun-29-23 06:20AM
Jun-21-23 08:41PM
May-23-23 04:05PM
May-17-23 06:35AM
May-16-23 02:34AM
May-10-23 10:45AM
May-09-23 06:05PM
May-02-23 10:01AM
Apr-18-23 08:41AM
Apr-05-23 08:00AM
11:15PM Loading…
Apr-04-23 11:15PM
Mar-30-23 08:00AM
Mar-29-23 05:36AM
Mar-07-23 08:00AM
Mar-03-23 08:11PM
Mar-01-23 10:33AM
Feb-28-23 07:45PM
Feb-27-23 08:00AM
Feb-24-23 05:10PM
Feb-23-23 08:00AM
Feb-22-23 10:00AM
Feb-21-23 04:05PM
Feb-20-23 10:00AM
Feb-03-23 02:15PM
Feb-02-23 12:00PM
Jan-30-23 10:20AM
Jan-27-23 12:47PM
Jan-23-23 04:14AM
Jan-09-23 08:00AM
Jan-06-23 06:00PM
Nov-22-22 08:00AM
Nov-17-22 08:00AM
Nov-10-22 05:32AM
Nov-09-22 08:00AM
Nov-08-22 06:05PM
Nov-04-22 08:00AM
Nov-02-22 10:01AM
Nov-01-22 01:01PM
Oct-24-22 12:02PM
Oct-20-22 08:00AM
Oct-17-22 08:00AM
Oct-10-22 08:00AM
Sep-21-22 08:00AM
Sep-19-22 08:00AM
Sep-17-22 08:36AM
Sep-15-22 04:06PM
Sep-12-22 09:32PM
Sep-09-22 03:10PM
Sep-08-22 05:13PM
Aug-11-22 11:10AM
Aug-10-22 04:35PM
Aug-09-22 06:15PM
Aug-02-22 04:05PM
Jul-27-22 08:00AM
Jul-20-22 05:26PM
Jul-17-22 10:46AM
Jun-15-22 08:19AM
May-23-22 08:00AM
May-17-22 06:46AM
May-10-22 05:45PM
May-05-22 06:45PM
May-03-22 08:00AM
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing OnabotulinumtoxinA, a biosimilar to BOTOX. The company also offers Resilient Hyaluronic Acid (RHA) dermal filler for the correction of moderate to severe dynamic facial wrinkles; RHA Redensity, a dermal filler for the treatment of moderate to severe dynamic perioral rhytids; and OPUL Relational Commerce Platform, a financial technology platform. It has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Moxie DwightSVP, GC & SecretarySep 06Sale17.0611,000187,70444,066Sep 07 05:37 PM
Moxie DwightSVP, GC & SecretarySep 05Sale17.8123,853424,92055,066Sep 07 05:37 PM
Foley Mark JCEOAug 03Sale22.5726,279593,151840,375Aug 04 05:07 PM
Foley Mark JCEOJul 03Sale24.9426,279655,333866,654Jul 05 09:11 PM
Schilke TobinCFOJul 03Sale25.041,70142,59379,896Jul 05 09:11 PM
Kolaja Carey OConnorDirectorJun 15Option Exercise18.122,50045,30019,061Jun 20 04:25 PM
Kolaja Carey OConnorDirectorJun 15Sale28.242,50070,60016,561Jun 20 04:25 PM
Foley Mark JCEOJun 09Sale30.7231,279960,928891,933Jun 13 08:09 PM
Sjuts Dustin SPresidentJun 09Sale30.825,000154,096147,347Jun 13 08:09 PM
Schilke TobinCFOJun 02Sale31.0050015,50080,828Jun 05 06:06 PM
Schilke TobinCFOJun 01Sale30.572,70182,57081,328Jun 05 06:06 PM
Foley Mark JCEOMay 15Sale34.5570,4472,433,725923,212May 16 08:29 PM
Schilke TobinCFOMay 15Sale34.5521,401739,33884,029May 16 08:29 PM
Moxie DwightSVP, GC & SecretaryMay 15Sale34.5521,401739,33869,165May 16 08:29 PM
Sjuts Dustin SPresidentMay 15Sale34.5521,015726,003152,347May 16 08:29 PM
Schilke TobinCFOMay 01Sale31.703,201101,47263,081May 02 04:01 PM
Schilke TobinCFOApr 03Sale32.153,201102,91266,282Apr 04 04:24 PM
Foley Mark JCEOMar 09Sale31.5970,3902,223,360823,351Mar 09 09:45 PM
Sjuts Dustin SPresidentMar 09Sale31.5921,508679,358123,934Mar 09 09:45 PM
Schilke TobinCFOMar 09Sale31.5918,517584,88473,222Mar 09 09:46 PM
Moxie DwightSVP, GC & SecretaryMar 09Sale31.5918,496584,22055,547Mar 09 09:46 PM
Schilke TobinCFOMar 01Sale33.503,201107,23449,390Mar 02 09:25 PM
Schilke TobinCFOFeb 01Sale34.603,201110,75554,676Feb 02 09:38 PM
Schilke TobinCFOJan 20Sale31.001,00031,00057,877Jan 23 05:35 PM
Schilke TobinCFOJan 09Sale27.163,701100,52558,877Jan 10 08:06 PM